本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Regenxbio Inc

9.12
+0.19002.13%
盘后9.120.00000.00%18:06 EDT
成交量:42.33万
成交额:389.54万
市值:4.61亿
市盈率:-2.66
高:9.43
开:8.75
低:8.75
收:8.93
52周最高:13.48
52周最低:5.04
股本:5,051.42万
流通股本:4,142.31万
量比:0.74
换手率:1.02%
股息:- -
股息率:- -
每股收益(TTM):-3.4333
每股收益(LYR):-4.5871
净资产收益率:-62.49%
总资产收益率:-17.88%
市净率:2.16
市盈率(LYR):-1.99

数据加载中...

2024/10/17

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/17

重要事件披露

Form 8-K - Current report
2024/08/06

重要事件披露

Form 8-K - Current report
2024/08/01

重要事件披露

Form 8-K - Current report
2024/08/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/01

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/13

重要事件披露

Form 8-K - Current report
2024/06/03

重要事件披露

Form 8-K - Current report
2024/05/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/08

重要事件披露

Form 8-K - Current report
2024/03/11

重要事件披露

Form 8-K - Current report
2024/03/07

[补充]招股说明书

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2024/03/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/27

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/27

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/27

重要事件披露

Form 8-K - Current report
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]